Abstract: PURPOSE: To investigate the clinical efficiency of glucocorticoid combined with lauromacrogol foam sclerotherapy for treating Kasabach-Merritt syndrome (phenomenon, KMS, KMP). METHODS: Sixteen patients (7 males and 9 females) with KMS (KMP) admitted in our hospital from January 2013 to December 2014 were included in this study. The patients aged from 5 days to 20 months (median: 3 months). Eight patients showed lesion in head and neck, 6 in extremities and 2 in trunk. All patients received intravenous injection of dexamethasone (0.5-0.75 mg/kg per day) for 7 days, followed by oral prednisone (3-5 mg/kg per day) every 2 days. One month later, the dose was gradually decreased until termination. Local lesion was treated by lauromacrogol foam sclerotherapy once per week with a schedule of 3-5 times in total. The size, texture, color and temperature of the lesion were monitored, and blood platelet count was performed regularly. RESULTS: The follow-up period was 6-24 months. Ten patients showed complete response after treatment, 3 showed obvious response and 3 showed disease progression. The total effective rate was 81.3%. CONCLUSIONS: Glucocorticoid combined with lauromacrogol foam sclerotherapy is effective for treating KMS (KMP), which can remarkably decrease the dose and duration of corticosteroids therapy, minimized the side effects of corticosteroids. Such therapy deserves further application in clinical practice.

Key words: Glucocorticoid, Lauromacrogol foam sclerotherapy, Kasabach-Merritt syndrome, Kasabach-Merritt 557/img_1.jpg674.02.0phenomenon